Search results
Results from the WOW.Com Content Network
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York.The company was founded in 1988. [2] Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company branched out into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a ...
This page was last edited on 14 February 2021, at 14:06 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
In 2014, Yancopoulos led the launch of the Regeneron Genetics Center, a major initiative in human genetic research that has sequenced exomes from over 1,000,000 people as of February 2020. [23] [24] Forbes magazine states Yancopoulos' financial stake in Regeneron has made him a billionaire. He is the first research and development chief in the ...
Regeneron commenced clinical testing of aflibercept in cancer in 2001. [25] In 2003, Regeneron signed a major deal with Aventis to develop aflibercept in the field of cancer. [ 26 ] In 2004 Regeneron started testing the compound, locally delivered, in proliferative eye diseases, [ 25 ] and in 2006 Regeneron and Bayer signed an agreement to ...
On 2 October 2020, Regeneron Pharmaceuticals announced that then-US President Donald Trump had received "a single 8 gram dose of REGN-COV2" after testing positive for SARS-CoV-2. [26] [27] The drug was provided by the company in response to a "compassionate use" (temporary authorization for use) request from the president's physicians. [26]
Odronextamab, sold under the brand name Ordspono, is a CD20 x CD3 bispecific monoclonal antibody that is used for the treatment of follicular lymphoma or diffuse large B-cell lymphoma.
Garetosmab is a fully human, experimental monoclonal antibody against activin-A.It has been tried in patients with fibrodysplasia ossificans progressiva and the manufacturer, Regeneron, also plans to test it in patients with obesity as an add-on to existing weight loss drugs such as GLP-1 agonists, in order to help patients maintain muscle mass during weight loss.
Sarilumab, sold under the brand name Kevzara, is a human monoclonal antibody medication against the interleukin-6 receptor. [6] Regeneron Pharmaceuticals and Sanofi developed the drug for the treatment of rheumatoid arthritis (RA), for which it received US FDA approval on 22 May 2017 and European Medicines Agency approval on 23 June 2017.